RECRUITMENT OF PHARMACIST FOR MOBILE HEALTH TEAMS ON CONTRACT BASIS UNDER RASTRIYA BALA SWASTHYA KARYAKRAM, NATIONAL HEALTH MISSION.
Post: Pharmacist - 40 posts
The leaked internal e-mails seem to show employees of one of the world's leading pharmaceutical companies calling for "celebrating" price rises for cancer drugs, a survey revealed.
When the pharmaceutical giant negotiated the price of pharmaceuticals in Spain, the pharmaceutical giant would have threatened to stop selling cancer treatments unless the Minister of Health agreed to price increases of up to 4,000 percent, The Spanish daily El Confidencial Digital said at the time. Price increases were made possible by a loophole that allows pharmaceutical companies to change the price of drugs if they are no longer branded with the same name.
The staff of Aspen Pharmacare, based in South Africa and having its European headquarters in Dublin, would have been traced to destroy stocks of life-saving drugs during a price conflict with the Spanish health service in 2014.
After buying five different cancer drugs from the British company GlaxoSmithKline (GSK), the company tried to sell drugs in Europe up to 40 times their previous price, The Times reported. In 2013, the price of a package of a chemotherapy drug called busulfan, used to treat leukemia, rose from £ 5.20 to £ 65.22 in England and Wales.
As a result of price restrictions imposed by the National Pharmaceutical Pricing Authority (NPPA), India's drug pricing regulator, earlier this year, many multinational stent manufacturers are considering withdrawing their products from high Range of the country by citing "non-viability".
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that it has launched Progesterone Capsules, 100 mg and 200 mg, a therapeutic equivalent generic version of Prometrium® (Progesterone) Capsules in the United States market, approved by the U.S. Food and Drug Administration (USFDA).
Novartis announced data from the Phase IV Multiple Sclerosis and clinical outcome and MRI in the US (MS-MRIUS) study, which confirmed the effectiveness of Gilenya® (fingolimod) in the real-world setting, supporting previous findings from Phase III trials. Results show that Gilenya impacted four key measures of MS disease activity (relapses, MRI lesions, disability progression and brain shrinkage), in people with relapsing-remitting multiple sclerosis (RRMS) for up to 16 months. This is also the first time a multicenter study has evaluated and shown that routine magnetic resonance imaging (MRI) scans taken in the every-day clinical setting can reliably be used to measure brain shrinkage, a key measure of disease progression, in people with RRMS. Full results are presented at the 69th American Academy of Neurology (AAN) Annual Meeting, in Boston, Massachusetts, USA.
Maharashtra Registered Pharmacists Association (MRPA) requested JP Nadda, union health minister to reconsider Union health ministry's proposal to empower Pharmacist (chemists) to supply alternative cheaper drugs (Generic) with same ingredients.